Metraipolis › archive › dc_d9567ccc03ca
Cost-utility analysis of eptinezumab for migraine prevention in Taiwan — Europe PMC PMID:41455879
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41455879
- DOI
- 10.1186/s13561-[numero omesso]-x
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T08:57:48.327Z
- SHA-256 of the archived text
262d735a6b24bf60ecd522d3e4ddf853ddaa22534b896e9bdde7bcaae5448597- Stable URL of this page
https://metraipolis.com/documento/dc_d9567ccc03ca
How to cite
Cost-utility analysis of eptinezumab for migraine prevention in Taiwan — Europe PMC PMID:41455879 — Europe PMC (en), https://europepmc.org/article/MED/41455879 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d9567ccc03ca (Metraipolis archive dc_d9567ccc03ca, sha256 262d735a6b24bf60ecd522d3e4ddf853ddaa22534b896e9bdde7bcaae5448597)
BibTeX
@misc{dcd9567ccc03ca,
title = {Cost-utility analysis of eptinezumab for migraine prevention in Taiwan — Europe PMC PMID:41455879},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41455879},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d9567ccc03ca; sha256 262d735a6b24bf60ecd522d3e4ddf853ddaa22534b896e9bdde7bcaae5448597},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41455879. Agents can read the archived copy with the MCP tool read_document.